0GO Stock Chart & Stats
€0.03
€0.02(160.00%)
At close: 4:00 PM EDT
€0.03
€0.02(160.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume3.00K
Average Volume (3M)N/A
Market Cap
€20.14M
Enterprise Value€3.06M
Total Cash (Recent Filing)€1.08M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-35.31
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,775,721,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.55
Price to Sales (P/S)523.56
P/FCF Ratio-3.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt is a durable financial strength: it lowers default and interest-rate risk, preserves flexibility to pursue partnering or licensing deals, and gives management time to negotiate non-dilutive collaborations. This structural capital flexibility supports long-term platform development despite cash burn.
Proprietary Nuvec® Delivery PlatformA platform technology that can be applied across vaccines, oncology and nucleic-acid therapeutics creates scalable, durable competitive potential: licensing and milestone-driven partnerships allow revenue leverage from multiple external programs, reducing the need for in-house commercialization and enabling broad addressable markets over time.
Lean Operating StructureA very small headcount indicates a low fixed-cost operating model suited to a partnership/licensing strategy. This structural lean footprint helps conserve cash, extend runway between financings, and enables the company to outsource R&D execution to partners, aligning costs with milestone-driven revenue opportunities.
Bears Say
Persistent Cash BurnNegative operating and free cash flow each year is a long-lasting constraint: it forces reliance on external funding or dilutive financings, limits ability to self-fund development or scale, and increases execution risk if partner deals or capital markets access slow down over multiple quarters.
Deep, Sustained Losses And Weak MarginsVery large negative margins and ongoing net losses erode shareholder equity and signal limited current commercial traction. Structurally, this reduces internal reinvestment capacity, pressures return metrics long-term, and makes the company more dependent on successful licensing deals or frequent capital raises to continue operations.
Small, Volatile Revenue Base And Partnership DependenceRevenue volatility and a low absolute top line reflect dependency on securing partnerships/milestones. Structurally, this creates uncertain cash inflows and makes planning, scaling, and investor confidence contingent on winning and executing collaborations, which are competitive and time-consuming to close.
N4 Pharma News
0GO FAQ
What was N4 Pharma PLC’s price range in the past 12 months?
N4 Pharma PLC lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is N4 Pharma PLC’s market cap?
N4 Pharma PLC’s market cap is €20.14M.
When is N4 Pharma PLC’s upcoming earnings report date?
N4 Pharma PLC’s upcoming earnings report date is Sep 24, 2026 which is in 57 days.
How were N4 Pharma PLC’s earnings last quarter?
N4 Pharma PLC released its earnings results on Jun 23, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is N4 Pharma PLC overvalued?
According to Wall Street analysts N4 Pharma PLC’s price is currently Overvalued.
Does N4 Pharma PLC pay dividends?
N4 Pharma PLC does not currently pay dividends.
What is N4 Pharma PLC’s EPS estimate?
N4 Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does N4 Pharma PLC have?
N4 Pharma PLC has 1,775,721,000 shares outstanding.
What happened to N4 Pharma PLC’s price movement after its last earnings report?
N4 Pharma PLC reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of N4 Pharma PLC?
Currently, no hedge funds are holding shares in DE:0GO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
N4 Pharma PLC
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Eco Animal Health
―
Chill Brands Group PLC
―
Mountfield
―
Provexis
―
Shield Therapeutics
―